Should Pharma Regain MES Leadership or Become the New IX Leaders?

Posted by Andrew Hughes on Tue, Jun 01, 2021

Since the advent of Manufacturing Execution Systems (MES, or MOM for those who prefer) in the late 1980s, life sciences, and especially pharmaceuticals finishing and packing, led the way in useful MES solutions. Some would argue that MES for pharma has reached maturity and there are few gains to be made. At LNS Research, we believe that change is just beginning and it is time for the pharma software industry to wake up or get severely disrupted by new players.

Many pharmaceutical companies, ranging from boutique startups to the global giants, have active Industrial Transformation (IX) programs that foresee structural changes in the way they operate. Existing pharma MES systems provide the necessary functionality for most operations but are hard to maintain, inflexible, and do not provide a data platform for other parts of the enterprise. Such integration will, inevitably, be a part of IX programs. 

Read More

Categories: Manufacturing Operations Management (MOM), Manufacturing Execution System (MES), Industrial Transformation / Digital Transformation, Industry 4.0 / Smart Manufacturing, Internet of Things (IoT), IX Platform, Big Pharma